Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery
Arkadeep Dhali, Jyotirmoy Biswas, Fayaz Khan, Ashish Sharma, Dushyant S. Dahiya, Saikat Mandal, Manideepa MajiObjectives:
The optimal timing of pancreatic enzyme replacement therapy (PERT) after pancreatic surgery for pancreatic cancer remains uncertain. We compared outcomes after early versus delayed PERT initiation in a real-world cohort.
Methods:
This retrospective cohort study used the TriNetX US Collaborative Network database. Adults with pancreatic cancer undergoing pancreatic surgery were categorized as early PERT if treatment was started within 1 month after surgery, and late PERT if started between 2 and 3 months after surgery. Outcomes were assessed from 90 to 730 days after the index event. Comparative analyses were performed after 1:1 propensity score matching.
Results:
Before matching, 3960 patients were identified in the late PERT cohort and 9807 in the early PERT cohort; after matching, 3948 patients were retained in each group. All-cause mortality was similar between the late and early PERT cohorts (1076/3871 [27.8%] vs. 1022/3831 [26.7%]; risk ratio [RR]: 1.042; 95% CI: 0.969-1.121;
Conclusions:
Delayed PERT initiation was not associated with higher mortality or emergency department utilization but was associated with higher diarrhea and hypoalbuminemia risk.